The current stock price of LFWD is 0.524 USD. In the past month the price decreased by -19.14%. In the past year, price decreased by -72.57%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.67 | 222.97B | ||
| ISRG | INTUITIVE SURGICAL INC | 65.23 | 201.33B | ||
| BSX | BOSTON SCIENTIFIC CORP | 32.84 | 143.55B | ||
| SYK | STRYKER CORP | 27.96 | 140.79B | ||
| IDXX | IDEXX LABORATORIES INC | 57.57 | 58.07B | ||
| BDX | BECTON DICKINSON AND CO | 13.36 | 55.24B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.12 | 49.40B | ||
| RMD | RESMED INC | 25.33 | 36.59B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.66 | 34.82B | ||
| DXCM | DEXCOM INC | 32.38 | 23.62B | ||
| PODD | INSULET CORP | 72.47 | 23.30B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.39 | 18.26B |
Lifeward Ltd. is a medical device company, which engages in the design, development and marketing of wearable robotic exoskeletons. The firm is engaged in designing, developing, and commercializing exoskeletons that allow individuals with mobility impairments or other medical conditions the ability to stand and walk again. The firm offers an exoskeleton that uses its tilt-sensor technology and an onboard computer and motion sensors to drive motorized legs that power movement. Lifeward designs are intended for people with paraplegia, a spinal cord injury resulting in complete or incomplete paralysis of the legs, having the use of their upper bodies and arms. The firm offers multiple products: ReWalk Personal, ReStore Exo-Suit, MYOLYN FES Cycling, and AlterG Anti-Gravity Systems. ReWalk Personal is designed for everyday use by paraplegic individuals at home and in their communities and is custom-fitted for each user. Lifeward Rehabilitation products are for use by paraplegia patients in the clinical rehabilitation environment.
LIFEWARD LTD
3 Hatnufa st. 6th fl., P.O. Box 161
Yokneam IL
Employees: 80
Phone: 97249590123
Lifeward Ltd. is a medical device company, which engages in the design, development and marketing of wearable robotic exoskeletons. The firm is engaged in designing, developing, and commercializing exoskeletons that allow individuals with mobility impairments or other medical conditions the ability to stand and walk again. The firm offers an exoskeleton that uses its tilt-sensor technology and an onboard computer and motion sensors to drive motorized legs that power movement. Lifeward designs are intended for people with paraplegia, a spinal cord injury resulting in complete or incomplete paralysis of the legs, having the use of their upper bodies and arms. The firm offers multiple products: ReWalk Personal, ReStore Exo-Suit, MYOLYN FES Cycling, and AlterG Anti-Gravity Systems. ReWalk Personal is designed for everyday use by paraplegic individuals at home and in their communities and is custom-fitted for each user. Lifeward Rehabilitation products are for use by paraplegia patients in the clinical rehabilitation environment.
The current stock price of LFWD is 0.524 USD. The price increased by 0.77% in the last trading session.
LFWD does not pay a dividend.
LFWD has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
LIFEWARD LTD (LFWD) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.86).
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on LFWD.
The Revenue of LIFEWARD LTD (LFWD) is expected to decline by -1.98% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
ChartMill assigns a fundamental rating of 3 / 10 to LFWD. While LFWD seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months LFWD reported a non-GAAP Earnings per Share(EPS) of -1.86. The EPS increased by 25.3% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -111.13% | ||
| ROE | -196.94% | ||
| Debt/Equity | 0 |
8 analysts have analysed LFWD and the average price target is 5.61 USD. This implies a price increase of 970.61% is expected in the next year compared to the current price of 0.524.
For the next year, analysts expect an EPS growth of 43.2% and a revenue growth -1.98% for LFWD